Ken Cacciatore
Stock Analyst at TD Cowen
(0.33)
# 4,311
Out of 5,182 analysts
13
Total ratings
30%
Success rate
-28.61%
Average return
Main Sectors:
Stocks Rated by Ken Cacciatore
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| ARQT Arcutis Biotherapeutics | Maintains: Outperform | $65 → $50 | $23.35 | +114.13% | 2 | Aug 9, 2023 | |
| BHC Bausch Health Companies | Downgrades: Market Perform | n/a | $5.65 | - | 1 | Jun 16, 2023 | |
| TAK Takeda Pharmaceutical Company | Maintains: Outperform | $30 → $20 | $16.62 | +20.34% | 4 | May 16, 2023 | |
| BLCO Bausch + Lomb | Initiates: Outperform | $35 | $16.31 | +114.59% | 1 | May 11, 2022 | |
| MOLN Molecular Partners AG | Initiates: Outperform | $50 | $4.24 | +1,079.25% | 1 | Jul 13, 2021 | |
| TARA Protara Therapeutics | Initiates: Outperform | $50 | $5.32 | +839.85% | 1 | Oct 19, 2020 | |
| BHVN Biohaven | Initiates: Outperform | $45 | $9.63 | +367.29% | 1 | Apr 17, 2020 | |
| AMRN Amarin Corporation | Initiates: Outperform | $460 | $14.07 | +3,169.37% | 1 | Mar 2, 2020 | |
| OPTN Option Therapeutics | Initiates: Outperform | $375 | $9.60 | +3,806.25% | 1 | Dec 18, 2019 |
Arcutis Biotherapeutics
Aug 9, 2023
Maintains: Outperform
Price Target: $65 → $50
Current: $23.35
Upside: +114.13%
Bausch Health Companies
Jun 16, 2023
Downgrades: Market Perform
Price Target: n/a
Current: $5.65
Upside: -
Takeda Pharmaceutical Company
May 16, 2023
Maintains: Outperform
Price Target: $30 → $20
Current: $16.62
Upside: +20.34%
Bausch + Lomb
May 11, 2022
Initiates: Outperform
Price Target: $35
Current: $16.31
Upside: +114.59%
Molecular Partners AG
Jul 13, 2021
Initiates: Outperform
Price Target: $50
Current: $4.24
Upside: +1,079.25%
Protara Therapeutics
Oct 19, 2020
Initiates: Outperform
Price Target: $50
Current: $5.32
Upside: +839.85%
Biohaven
Apr 17, 2020
Initiates: Outperform
Price Target: $45
Current: $9.63
Upside: +367.29%
Amarin Corporation
Mar 2, 2020
Initiates: Outperform
Price Target: $460
Current: $14.07
Upside: +3,169.37%
Option Therapeutics
Dec 18, 2019
Initiates: Outperform
Price Target: $375
Current: $9.60
Upside: +3,806.25%